Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB575 in Healthy Participants and Atopic Dermatitis Participants
NCT07488065Phase 1Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HBM7575 in atopic dermatitis (AD) (8 arms), sponsored by Kelun-Biotech. Primary endpoints: Number of participants with adverse events (AEs) /TEAEs at Day 225 and Proportion of participants achieving EASI-75 at Week 16. Started Mar 2026; status: recruiting.
02
Drugs
HBM7575
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07488065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07488065.